Marks Group Wealth Management’s BioNTech BNTX Stock Holding History

Marks Group Wealth Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,454	Closed	-$307K	–	352
2026 Q1	$307K	Buy	3,454 +476	+16%	+$48.9K	0.03%	290
2025 Q4	$284K	Buy	+2,978	New	+$300K	0.03%	294
2024 Q3	–	Sell	-3,438	Closed	-$276K	–	296
2024 Q2	$276K	Sell	3,438 -213	-6%	-$19.5K	0.03%	264
2024 Q1	$337K	Sell	3,651 -188	-5%	-$18K	0.04%	255
2023 Q4	$405K	Buy	+3,839	New	+$387K	0.05%	231

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Marks Group Wealth Management's BNTX Position: Q2 2026 in Review

Marks Group Wealth Management sold out of BioNTech (BNTX) in Q2 2026, closing a stake of 3,454 shares — an estimated $307K sold.

Marks Group Wealth Management first reported a position in BNTX in Q4 2023 and held it in 5 quarters. The position peaked at $405K in Q4 2023. 283 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Marks Group Wealth Management reported no remaining BioNTech position as of Q2 2026 after selling out during the quarter.
Marks Group Wealth Management sold 3,454 BioNTech shares in Q2 2026, an estimated $307K.
Marks Group Wealth Management first reported a position in BioNTech in Q4 2023 and held it in 5 quarters.
Marks Group Wealth Management's BioNTech position peaked at $405K in Q4 2023.
283 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.